272 related articles for article (PubMed ID: 27596438)
21. Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma.
Ferretti LP; Böhi F; Leslie Pedrioli DM; Cheng PF; Ferrari E; Baumgaertner P; Alvarado-Diaz A; Sella F; Cereghetti A; Turko P; Wright RH; De Bock K; Speiser DE; Ferrari R; Levesque MP; Hottiger MO
Cancer Res; 2023 Dec; 83(23):3974-3988. PubMed ID: 37729428
[TBL] [Abstract][Full Text] [Related]
22. SHP-2-upregulated ZEB1 is important for PDGFRα-driven glioma epithelial-mesenchymal transition and invasion in mice and humans.
Zhang L; Zhang W; Li Y; Alvarez A; Li Z; Wang Y; Song L; Lv D; Nakano I; Hu B; Cheng SY; Feng H
Oncogene; 2016 Oct; 35(43):5641-5652. PubMed ID: 27041571
[TBL] [Abstract][Full Text] [Related]
23. ZEB1 is neither sufficient nor required for epithelial-mesenchymal transition in LS174T colorectal cancer cells.
Jägle S; Dertmann A; Schrempp M; Hecht A
Biochem Biophys Res Commun; 2017 Jan; 482(4):1226-1232. PubMed ID: 27923654
[TBL] [Abstract][Full Text] [Related]
24. Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells.
Kfir-Elirachman K; Ortenberg R; Vizel B; Besser MJ; Barshack I; Schachter J; Nemlich Y; Markel G
Neoplasia; 2018 Apr; 20(4):401-409. PubMed ID: 29558679
[TBL] [Abstract][Full Text] [Related]
25. MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
Rose AA; Annis MG; Frederick DT; Biondini M; Dong Z; Kwong L; Chin L; Keler T; Hawthorne T; Watson IR; Flaherty KT; Siegel PM
Clin Cancer Res; 2016 Dec; 22(24):6088-6098. PubMed ID: 27515299
[TBL] [Abstract][Full Text] [Related]
26. Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs.
Makino E; Gutmann V; Kosnopfel C; Niessner H; Forschner A; Garbe C; Sinnberg T; Schittek B
Cell Death Dis; 2018 Sep; 9(9):930. PubMed ID: 30206212
[TBL] [Abstract][Full Text] [Related]
27. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W
Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155
[No Abstract] [Full Text] [Related]
28. EMT-associated factors promote invasive properties of uveal melanoma cells.
Asnaghi L; Gezgin G; Tripathy A; Handa JT; Merbs SL; van der Velden PA; Jager MJ; Harbour JW; Eberhart CG
Mol Vis; 2015; 21():919-29. PubMed ID: 26321866
[TBL] [Abstract][Full Text] [Related]
29. Intrinsic Balance between ZEB Family Members Is Important for Melanocyte Homeostasis and Melanoma Progression.
Bruneel K; Verstappe J; Vandamme N; Berx G
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32796736
[TBL] [Abstract][Full Text] [Related]
30. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
[TBL] [Abstract][Full Text] [Related]
31. ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage.
Song N; Jing W; Li C; Bai M; Cheng Y; Li H; Hou K; Li Y; Wang K; Li Z; Liu Y; Qu X; Che X
Cell Cycle; 2018; 17(5):595-604. PubMed ID: 29157079
[TBL] [Abstract][Full Text] [Related]
32. A genetic cell context-dependent role for ZEB1 in lung cancer.
Zhang T; Guo L; Creighton CJ; Lu Q; Gibbons DL; Yi ES; Deng B; Molina JR; Sun Z; Yang P; Yang Y
Nat Commun; 2016 Jul; 7():12231. PubMed ID: 27456471
[TBL] [Abstract][Full Text] [Related]
33. A novel ZEB1/HAS2 positive feedback loop promotes EMT in breast cancer.
Preca BT; Bajdak K; Mock K; Lehmann W; Sundararajan V; Bronsert P; Matzge-Ogi A; Orian-Rousseau V; Brabletz S; Brabletz T; Maurer J; Stemmler MP
Oncotarget; 2017 Feb; 8(7):11530-11543. PubMed ID: 28086235
[TBL] [Abstract][Full Text] [Related]
34. The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancer.
Hanrahan K; O'Neill A; Prencipe M; Bugler J; Murphy L; Fabre A; Puhr M; Culig Z; Murphy K; Watson RW
Mol Oncol; 2017 Mar; 11(3):251-265. PubMed ID: 28133913
[TBL] [Abstract][Full Text] [Related]
35. Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy.
Talebi A; Dehairs J; Rambow F; Rogiers A; Nittner D; Derua R; Vanderhoydonc F; Duarte JAG; Bosisio F; Van den Eynde K; Nys K; Pérez MV; Agostinis P; Waelkens E; Van den Oord J; Fendt SM; Marine JC; Swinnen JV
Nat Commun; 2018 Jun; 9(1):2500. PubMed ID: 29950559
[TBL] [Abstract][Full Text] [Related]
36. SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma.
Hüser L; Sachindra S; Granados K; Federico A; Larribère L; Novak D; Umansky V; Altevogt P; Utikal J
Int J Cancer; 2018 Dec; 143(12):3131-3142. PubMed ID: 29905375
[TBL] [Abstract][Full Text] [Related]
37. Src promotes EGF-induced epithelial-to-mesenchymal transition and migration in gastric cancer cells by upregulating ZEB1 and ZEB2 through AKT.
Zhao L; Li X; Song N; Li A; Hou K; Qu X; Che X; Liu Y
Cell Biol Int; 2018 Mar; 42(3):294-302. PubMed ID: 29052277
[TBL] [Abstract][Full Text] [Related]
38. Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.
Song C; Piva M; Sun L; Hong A; Moriceau G; Kong X; Zhang H; Lomeli S; Qian J; Yu CC; Damoiseaux R; Kelley MC; Dahlman KB; Scumpia PO; Sosman JA; Johnson DB; Ribas A; Hugo W; Lo RS
Cancer Discov; 2017 Nov; 7(11):1248-1265. PubMed ID: 28864476
[TBL] [Abstract][Full Text] [Related]
39. MSX1-Induced Neural Crest-Like Reprogramming Promotes Melanoma Progression.
Heppt MV; Wang JX; Hristova DM; Wei Z; Li L; Evans B; Beqiri M; Zaman S; Zhang J; Irmler M; Berking C; Besch R; Beckers J; Rauscher FJ; Sturm RA; Fisher DE; Herlyn M; Fukunaga-Kalabis M
J Invest Dermatol; 2018 Jan; 138(1):141-149. PubMed ID: 28927893
[TBL] [Abstract][Full Text] [Related]
40. Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells.
Zhao K; Lu Y; Chen Y; Cheng J; Zhang W
Exp Cell Res; 2020 May; 390(2):111942. PubMed ID: 32173467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
